Effect of drug efflux transporters on placental transport of antiretroviral agent Abacavir (cas 136470-78-5)

Add time:09/09/2019    Source:sciencedirect.com

Abacavir is as a frequent part of combination antiretroviral therapy used in pregnant women. The aim of this study was to investigate, using in vitro, in situ and ex vivo experimental approaches, whether the transplacental pharmacokinetics of abacavir is affected by ATP-binding cassette (ABC) efflux transporters functionally expressed in the placenta: P-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2), multidrug resistance-associated protein 2 (ABCC2) and multidrug resistance-associated protein 5 (ABCC5). In vitro transport assays revealed that abacavir is a substrate of human ABCB1 and ABCG2 transporters but not of ABCC2 or ABCC5. In addition, in situ experiments using dually perfused rat term placenta confirmed interactions of abacavir with placental Abcb1/Abcg2. In contrast, uptake studies in human placental villous fragments did not reveal any interaction of abacavir with efflux transporters suggesting a large contribution of passive diffusion and/or influx mechanisms to net transplacental abacavir transfer.

We also recommend Trading Suppliers and Manufacturers of Abacavir (cas 136470-78-5). Pls Click Website Link as below: cas 136470-78-5 suppliers

Prev:Abacavir (cas 136470-78-5) and cardiovascular disease: A critical look at the data
Next:Monitoring Abacavir (cas 136470-78-5) bioactivation in humans: Screening for an aldehyde metabolite)